News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ligand Pharmaceuticals Inc. (LGND) Exercises First Option To Buy Down ONTAK Royalties


10/19/2005 5:12:01 PM

SAN DIEGO--(BUSINESS WIRE)--Jan. 7, 2005--Ligand Pharmaceuticals (NASDAQ:LGND) announced today it has exercised the first option under its November 2004 agreement with Eli Lilly and Company (NYSE:LLY) to buy down a portion of the royalties payable to Lilly on sales of Ligand's marketed cancer drug ONTAK(R) (denileukin diftitox) in the United States. Ligand recorded sales of $34.3 million for ONTAK in calendar year 2003 and $25.9 million in the first three quarters of 2004.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES